All In Biotech

Drug Trial Radar · NCT01472614

Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

Effect of Add-on Therapy With DLBS3233 on Glycemic Control, Lipid Profile, and Adiponectin in Patients With Type-2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: May 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

54

Actual

Start

Sep 2011

Primary completion

Jan 2013

Study completion Apr 2013

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
First posted
Nov 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of an add-on therapy with DLBS3233 in improving blood glucose control, lipid profile, and adiponectin in subjects with type-2 diabetes mellitus.

Conditions

  • Type-2 Diabetes Mellitus

Interventions

  • DLBS3233Drug

    Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of A1c levelTime frame: 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Private Clinic at Jl. Prof. Dr. Moestopo 164

    Surabaya, East Java, Indonesia

  • Surabaya Diabetes and Nutrition Centre, Dr. Soetomo Hospital

    Surabaya, East Java, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.